only with
Healthcare
Large-cap - With a market cap of ₹1141.83 Cr.
| EX-Date | Purpose |
|---|---|
| 14 05 2021 | Dividend & Audited Results |
| 05 08 2021 | Quarterly Results |
| 26 10 2021 | Quarterly Results |
| 25 01 2022 | Quarterly Results |
| 10 05 2022 | Dividend & Audited Results |
| 29 07 2022 | Quarterly Results |
| 04 11 2022 | Quarterly Results |
| 25 01 2023 | Quarterly Results |
| 12 05 2023 | Audited Results & Quarterly Results & Final Dividend |
| 26 07 2023 | Quarterly Results |
| 27 10 2023 | Quarterly Results |
| 22 01 2024 | Quarterly Results (Revised) |
| 25 01 2024 | Quarterly Results |
| 10 05 2024 | Audited Results & Final Dividend |
| 29 10 2024 | Quarterly Results |
| 13 05 2025 | Audited Results & Final Dividend |
| 25 07 2025 | Quarterly Results |
| 30 10 2025 | Quarterly Results |
| 23 01 2026 | Quarterly Results |
| 13 05 2026 | Quarterly Results & Audited Results & Final Dividend |
News
Cipla’s consolidated net profit falls 55% in Q4
The total consolidated income of the company decreased by 4.70% at Rs 6,689.36 crore for Q4FY26
Cipla’s arm gets USFDA’s final nod for Albuterol Sulfate Inhalation Aerosol
This approval enhances Cipla’s U.S. respiratory portfolio and reinforces its leadership in the Albuterol inhalation category
USFDA concludes inspection at Cipla’s Goa manufacturing facility
On conclusion of the inspection, the Company received two inspectional observations in Form 483
Cipla gets nod to invest upto $100 million in Cipla (EU)
The board at its meeting held on March 19, 2026 has approved the same
Cipla’s arm recalling over 400 cartons of Nilotinib Capsules due to manufacturing issue
Cipla USA, Inc had initiated the Class III voluntary recall on February 18, 2026
Cipla’s arm incorporates subsidiary in Kingdom of Saudi Arabia
Cipla Middle East Company has been incorporated with the objective of establishing a legal entity for manufacturing and distribution of pharmaceutical products
Cipla’s arm receives two inspectional observations from USFDA
InvaGen has received two inspectional observations for its manufacturing facility located in Long Island
Cipla’s consolidated net profit drops 57% in Q3
The company’s consolidated total income decreased by 0.19% at Rs 7,280.82 crore for Q3FY26
Cipla inks pact with ImmunoACT to commercialize talicabtagene autoleucel in Africa
As part of this collaboration, ImmunoACT will manufacture the product and the company will commercialize in the licensed African territories
Cipla launches orally inhaled insulin in India
Afrezza is rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy
Cipla launches ‘Yurpeak’
Yurpeak is one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus
Cipla completes acquisition of 100% stake in Inzpera Healthsciences
Accordingly, Inzpera has now become a wholly owned subsidiary of the Company
Cipla launches therapy for Knee Osteoarthritis ‘Ciplostem’
The company has partnered with Stempeutics Research to launch Ciplostem
Cipla launches integrated lung diagnostics, wellness centre in Delhi
It will be India’s first-of-its-kind integrated lung diagnostics and wellness centre
Cipla to acquire Inzpera Healthsciences
Upon acquisition, Inzpera will become wholly owned subsidiary of the company
Cipla reports 4% rise in Q2 consolidated net profit
The consolidated total income of the company increased by 8.52% at Rs 7,858.39 crore for Q2FY26
Cipla enters into agreement with Eli Lilly and Company
Cipla has the rights to distribute and promote Yurpeak--the second brand of tirzepatide in India
Cipla’s arm recalling over 20,000 packs of Ibuterol Sulfate Inhalation Aerosol
The company is recalling 20,352 packs of the inhalation drug due to Failed Stability Specifications
Cipla’s Bengaluru manufacturing facility classified as VAI by USFDA
USFDA had conducted the inspection at said facility from May 26 to May 30, 2025
Cipla reports 10% rise in Q1 consolidated net profit
The total consolidated income of the company increased by 5.28% at Rs 7,216.03 crore for Q1FY26
Cipla signs definitive agreements for investment in iCaltech Innovations
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care
USFDA concludes cGMP inspection at Cipla’s Bengaluru manufacturing facility
On conclusion of the inspection, the company received one observation in Form 483
Cipla’s arm incorporates new wholly owned subsidiary in Germany
CiplaRna has been incorporated with the objective of establishing a laboratory for mRNA-based formulation and drug development support
Cipla’s arm acquires 26% stake in AMPIN Energy C&I Eighteen
Earlier, Jay Precision Pharmaceuticals had entered into Share Purchase, Subscription and Shareholder’s Agreement
Cipla’s arm inks pact to acquire 26% stake in AMPIN Energy C&I Eighteen
The total consideration to be paid for the said acquisition is up to Rs 1.46 crore
Cipla’s arm’s Mahape facility classified as VAI by USFDA
USFDA had conducted the inspection at said facility from February 18 to February 20, 2025
Cipla reports 30% rise in Q4 consolidated net profit
The total consolidated income of the company increased by 9.46% at Rs 7019.15 crore for Q4FY25
Cipla’s arm’s Goa facility classified as VAI by USFDA
USFDA had conducted the inspection at said facility from January 14 to January 20, 2025
Cipla gets USFDA’s final approval for generic cancer drug
The product is expected to be launched in H1 FY 2025-26 in the United States of America
Cipla gets USFDA’s final nod for Nilotinib Capsules
Nilotinib is an oncology category product in capsule form for oral consumption
USFDA concludes cGMP inspection at analytical testing facility of Cipla’s arm
On conclusion of the inspection, Sitec received two observations in Form 483
USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated
USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024
Cipla to invest in Cipla Medpro South Africa Proprietary
The investment is expected to be completed on or before February 28, 2025
Cipla reports 47% rise in Q3 consolidated net profit
Total consolidated income of the company increased by 7.46% at Rs 7294.58 crore for Q3FY25
Cipla’s arm gets one observation for Goa facility
USFDA has conducted an inspection at the manufacturing facility of Medispray Laboratories
Cipla launches mobile application for asthma screening
The mobile application is designed to enable the first line of screening for asthma in India
Cipla secures approval for distribution, marketing of Afrezza Inhalation Powder in India
This is the first and only noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus
USFDA concludes inspection at Cipla’s manufacturing facility in Bengaluru
On conclusion of the inspection, the Company received 8 observations in Form 483
Cipla’s consolidated net profit rises 13% in Q2FY25
Consolidated total income of the company increased by 5.65% at Rs 7,241.63 crore for Q2FY25
Cipla’s arm to acquire 6.9% stake held by Jiangsu Xidi Pharmaceuticals in China-based unit
Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the Company
Cipla’s arm signs agreement for acquisition of business undertaking from Ivia Beaute
This strategic move is aligned with Cipla’s focus on enhancing its consumer healthcare and wellness portfolio
USFDA concludes routine cGMP inspection at Cipla’s manufacturing facility in Patalganga
On conclusion of the inspection, the company has received 6 inspectional observations in Form 483
Cipla partners with Sanofi India
Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium
Cipla’s arm completes sale of entire shareholding in Wellthy
The consideration received from such sale is Rs 59.71 lakh
Cipla transfers Generics Business Undertaking to Cipla Pharma and Life Sciences
The company had received approval from board of directors to transfer Generics Business Undertaking
Cipla secures approval to market novel antibiotic plazomicin in India
Plazomicin’s introduction in India underscores Cipla’s proactive response to the urgent global challenge of antimicrobial resistance
Cipla ties up with CSIR-CDRI
The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis
Cipla’s arm completes acquisition of 100% equity stake in Actor Pharma
Accordingly, Actor will now be a wholly owned step-down subsidiary of the Company
Cipla acquires additional stake in GoApptiv
Accordingly, Cipla will now hold 22.99% stake on a fully diluted basis in GoApptiv
Cipla’s arms incorporate wholly owned subsidiary in Mexico
Mexicip is incorporated with an objective of sale and distribution of pharmaceutical drugs in Mexico
Cipla reports 32% rise in Q3 consolidated net profit
Total consolidated income of the company increased by 14.58% at Rs 6788.44 crore for Q3FY24
Cipla’s arm to incorporate JV Company in USA
The JV entity is being incorporated with an objective of commercialising novel cell therapy products in USA, Japan and EU region
Cipla to further invest Rs 42 crore in GoApptiv
With the completion of this deal, Cipla’s total stake in GoApptiv will increase to 22.99% on a fully diluted basis
Cipla’s arm recalls one lot of Vigabatrin for oral solution USP 500 mg
The affected lot is NB301030, with an expiration date of March 2025
Cipla’s arm acquires additional 15.10% stake in Cipla Maroc SA
Accordingly, Cipla EU will now hold 75.10% stake in the JV Co.
Cipla’s Pithampur manufacturing facility gets warning letter from USFDA
The Company will respond to the Warning Letter within the stipulated timelines and work closely with the USFDA
Cipla executes facility demand guarantee for extending general banking facilities
The company has executed a Facility Demand Guarantee of South African Rand 945 million
Cipla’s arms complete sale of entire 51.18% stake in CQCIL
Accordingly, CQCIL has now ceased to be a subsidiary of the company with effect from November 14, 2023
Cipla gets nod to transfer generics business undertaking
The Board of Directors of the company at its meeting held on November 06, 2023 have inter alia, approved the same
Cipla reports 45% rise in Q2 consolidated net profit
Total consolidated income of the company increased by 15.17% at Rs 6854.47 crore for Q2FY24
Cipla divests 51% stake in Saba Investment, UAE
Cipla, Saba Investment, UAE and Shibham Group Holding, UAE have executed Share Purchase agreement on September 28, 2023
Cipla launches drone-powered critical medicine delivery in Himachal Pradesh
The firm aims to deliver medicines for cardiac, respiratory and other essential chronic therapies as part of the initiative
USFDA issues 5 inspectional observations to New York facility of Cipla’s arm
The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
Cipla’s arm to acquire 100% stake in Actor Pharma
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost synergies in the South African market
Cipla’s associate company incorporates wholly owned subsidiary
The creation of Pactiv as a separate entity allows GoApptiv to segregate its business into distinct sectors i.e., technology and pharmaceuticals
Cipla reports 41% rise in Q1 consolidated net profit
Total consolidated income of the company increased by 18.01% at Rs 6,465.18 crore for Q1FY24
Cipla’s arm recalling six batches of Albuterol Sulfate inhalation Aerosol in US
These six batches were distributed nationwide to wholesalers and retailers
Cipla to sell entire stake of 51% in Saba Investment
Consideration to be received from such sale/disposal is $6.50 million
Cipla reports 41% rise in Q4 consolidated net profit
Total consolidated income of the company increased by 10.32% at Rs 5873.93 crore for Q4FY23
USFDA conducts routine cGMP inspection at manufacturing facility of Cipla’s arm
The inspection concluded with zero Form 483 observations
Cipla to sell 51.18% stake in Cipla Quality Chemical Industries
The proposed sale is expected to be completed by May 31, 2023
Cipla gets 8 inspectional observations from USFDA for Pithampur facility
USFDA has conducted a cGMP inspection at Cipla’s Pithampur manufacturing facility
Cipla reports 7% rise in Q3 consolidated net profit
Total consolidated income of the company increased 6.36% at Rs 5,924.53 crore for Q3FY23
Cipla launches Cippoint for non-communicable diseases, infectious disease
Cippoint aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience
Cipla’s arm signs definitive agreements for equity investment in Ethris GmbH
A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris’ innovative portfolio in Cipla’s key emerging markets
Cipla eyeing higher capital expenditure on automation for three more years
The company has started its investment journey on the automation front two years ago and has already been recognised for its work by multiple bodies
Cipla launches Leuprolide Acetate Injection Depot 22.5mg
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection
USFDA designates Cipla’s Goa plant as ’Official Action Indicated’
The USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved
Cipla reports 12% rise in Q2 consolidated net profit
Total consolidated income of the company increased by 6.65% at Rs 5951.49 crore for Q2FY23
Cipla’s arm recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution
The company is recalling the affected lot due to ‘lack of assurance of sterility: environmental monitoring failure’
Cipla’s Indore OSD plant designated by WEF as ‘Advanced 4IR Lighthouse’
The organization is amongst the first pharmaceutical companies in India & Asia to be part of the Global Lighthouse Network.
Cipla gets EIR from USFDA for Indore plant
The USFDA had conducted product-specific pre-approval inspection at the Indore plant on June 27 and July 1
Cipla receives USFDA’s approval for Lenalidomide Capsule
The product will be available for shipping soon
Cipla’s arm to pick up 13.10% stake in Jiangsu
Post-acquisition, Cipla EU’s stake in the subsidiary, will increase to 93.10%
Cipla dissolves step down wholly owned subsidiary
Cipla Med pro Holdings was a dormant entity and this dissolution will not affect performance or revenue of the company
Cipla gets 6 observations from USFDA for Goa plant
There are no data integrity observations
Cipla’s arm recalls 7992 bottles of Difluprednate Ophthalmic Emulsion in US market
The recalling of the lot is due to ‘lack of assurance of sterility’
Cipla eyeing to scale up US core formulations sales
Besides, the company is betting big on digitisation
Cipla’s arm to acquire additional 19.16% stake in Cipla Maroc
Upon completion of acquisition, Cipla EU will hold 79.16% stake in the JV Co and balance 20.84% stake will be held by Cooper Pharma
Cipla’s arm inks definitive agreements to acquire Endura Mass
CHL shall immediately initiate the distribution and marketing of the said products pending the closure of the proposed acquisition
USFDA conducts pre-approval inspection at Cipla’s Indore plant
The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at the said plant
Cipla signs definitive agreements for acquisition of 21.05% stake in Achira Labs
This investment will facilitate a Cipla entity’s strategic participation in the Poe diagnostics and AMR space